Skip to Content

Lithobid FDA Alerts

The FDA Alert(s) below may be specifically about Lithobid or relate to a group or class of drugs which include Lithobid (lithium).

MedWatch Safety Alerts are distributed by the FDA and published by Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.

Recent FDA Alert(s) for lithium

Carbolith (lithium carbonate)

Dec 9, 2004

Audience: Neuropsychiatric healthcare professionals and consumers

The FDA advised consumers about a Canadian recall of Carbolith (lithium carbonate) 150 mg capsules distributed in Canada by Valeant Canada Limited. Although Carbolith is not an FDA-approved product, FDA is investigating several Internet websites advertising Carbolith for sale to U.S. consumers. Carbolith 150 mg capsules are used in the treatment of manic-depressive illness. The company's recent testing led to the conclusion that the product may not deliver adequate amounts of the drug to ensure effective treatment. U.S. consumers who have taken it for the treatment of manic-depressive illness could experience adverse events associated with lowered blood lithium levels.

[December 8, 2004 - Talk Paper - FDA]

More Lithobid Resources